Join Eupraxia Pharmaceuticals for a webinar featuring members of company management who will discuss positive data from the highest-dose cohort in the ongoing RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE), and plans for the expansion of EP-104GI development programs.

The Phase 1b/2a part of the RESOLVE trial is a multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically confirmed active EoE. EP-104GI is a long-acting submucosal corticosteroid formulation to be injected within esophageal tissues, which has the potential to increase patient adherence by requiring fewer interventions while addressing local inflammation.

A live question and answer session will follow the formal presentations.